Pharmacogenomic testing: Knowing more, doing better

J. E. Lunshof, D. Gurwitz*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The clinical uptake of pharmacogenomic (PGx) testing and genotype-based prescribing has been disappointingly slow even though research on PGx is thriving. A recent survey on the adoption of PGx testing by US physicians suggests that this trend may start changing for the better. 1 Acquiring more knowledge of PGx tests and their clinical significance during graduate and postgraduate education will enable physicians to make better use of the available and upcoming PGx diagnostics in clinical practice.

Original languageEnglish
Pages (from-to)387-389
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume91
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Dive into the research topics of 'Pharmacogenomic testing: Knowing more, doing better'. Together they form a unique fingerprint.

Cite this